To more effectively transition novel immunotherapies from the clinical trial phase to the standard of care, researchers are relying on state-of-the-art methods for monitoring immune responses in patients.
The Immune Monitoring Facility, which is part of the Ludwig Center for Cancer Immunotherapy, provides the latest technology and expertise to assist researchers in designing and performing different types of immune assays in the course of a clinical study.
Our main objectives are to:
- Coordinate immune monitoring for clinical trials of new cancer immunotherapies
- Develop, optimize, and validate new technologies for immune monitoring
- Provide standardized and modern immune-based assays to monitor patients receiving novel immunotherapy
- Promote the development of new biomarkers
